Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience

Roberto Petrioli; Edoardo Francini; Franco Roviello; Daniele Marrelli; Anna Ida Fiaschi; Letizia Laera; Giulia Rossi; V. Bianco; S. Brozzetti; Giandomenico Roviello

doi:10.1007/s00280-015-2715-x

Back

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience

Journal article

Peer reviewed

Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience

Roberto Petrioli, Edoardo Francini, Franco Roviello, Daniele Marrelli, Anna Ida Fiaschi, Letizia Laera, Giulia Rossi, V. Bianco, S. Brozzetti and Giandomenico Roviello

Cancer chemotherapy and pharmacology, Vol.75(5), pp.941-947

05/01/2015

DOI: 10.1007/s00280-015-2715-x

PMID: 25743995

View Online

Abstract

The aim of this study was to evaluate the activity and safety of epirubicin (EPI), oxaliplatin (l-OHP) and 5fluorouracil (5FU) (EOF) followed by docetaxel (D), l-OHP and 5FU (DOF) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Forty-five patients were enrolled: 26 gastric and 19 GEJ cancer. Median age was 69 years (range 34-83); ECOG performance status was 0-1 in 37 patients. Treatment consisted of EPI 50 mg/m(2) combined with l-OHP 130 mg/m(2) on day 1 and continuous infusion 5FU 750 mg/m(2) days 1-5 (EOF), every 3 weeks for a maximum of 4 cycles. After EOF completion, patients received D 70 mg/m(2) combined with l-OHP 130 mg/m(2) on day 1 and continuous infusion 5FU 750 mg/m(2) days 1-5 (DOF), every 3 weeks for a maximum of 4 cycles. After sequential EOF/DOF, the overall response rate was 51.1 % (95 % CI 35.7-66.2 %) and 93.3 % of patients were progression free 6 months after the onset of chemotherapy. The median progression-free survival was 9.5 months (95 % CI 8.0-11.9 months), and the median overall survival was 15.8 months (95 % CI 13.6-18.9 months). Grade 3 neutropenia was observed in 15 patients (33.3 %) after sequential EOF/DOF. The sequential treatment EOF/DOF is feasible in well-selected patients with advanced gastric or GEJ cancer and shows encouraging survival results.

Life Sciences & Biomedicine

Oncology

Pharmacology & Pharmacy

Science & Technology

Details

Title: Subtitle: Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience
Creators: Roberto Petrioli - University of Siena
Edoardo Francini - Policlinico Umberto I
Franco Roviello - University of Siena
Daniele Marrelli - University of Siena
Anna Ida Fiaschi - University of Siena
Letizia Laera - University of Siena
Giulia Rossi - University of Siena
V. Bianco - Policlinico Umberto I
S. Brozzetti - Policlinico Umberto I
Giandomenico Roviello - University of Siena
Resource Type: Journal article
Publication Details: Cancer chemotherapy and pharmacology, Vol.75(5), pp.941-947
DOI: 10.1007/s00280-015-2715-x
PMID: 25743995
NLM abbreviation: Cancer Chemother Pharmacol
ISSN: 0344-5704
eISSN: 1432-0843
Publisher: Springer Nature
Number of pages: 7
Language: English
Date published: 05/01/2015
Academic Unit: Internal Medicine
Record Identifier: 9985221247002771

Metrics

2 Record Views

24 Times Cited - Web of Science